CTLA4 and non-small cell lung carcinoma: Check‐Mate 227 and Check‐Mate 9LA study demonstrated that combination of nivolumab (anti‐PD‐1) + ipilimumab (anti‐CTLA‐4) as the first line treatment improved survival in NSCLC.3, 5